COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Coya Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.20−0.05 (-1.18%)
Close on Oct 19, 2026
- Market cap
- $98.52M
- P/E (TTM)
- –
- Dividend yield
- –
Coya Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Market Cap | $98.52M | $166.30M |
| Enterprise Value | $55.34M | $87.12M |
| PS Ratio | 12.29 | 3.60 |
| PB Ratio | 2.28 | 2.03 |
| P/TBV Ratio | 2.28 | 2.31 |
Enterprise value
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 6.90 | 2.43 |
Income (trailing twelve months)
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Revenue | $8.02M | $57.94M |
| Operating Income | -$23.15M | -$21.49M |
| Net Income | -$21.67M | -$22.46M |
| EBITDA | -$23.15M | -$17.14M |
| EPS (Diluted) | -$1.07 | -$0.83 |
Margins
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -288.7% | -44.5% |
| Profit Margin | -270.2% | -39.2% |
| EBITDA Margin | -288.7% | -31.3% |
Returns
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -60.5% | -53.2% |
| Return on Assets (ROA) | -53.7% | -41.0% |
| Return on Capital Employed (ROCE) | -52.9% | -38.0% |
Growth
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 1793.8% | 6.01% |
Balance sheet
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $43.18M | $62.64M |
| Net Cash (Debt) | $43.18M | $15.77M |
| Net Cash Per Share | $1.84 | $0.66 |
| Equity (Book Value) | $43.28M | $48.61M |
| Book Value Per Share | $1.84 | $1.36 |
| Tangible Book Value | $43.28M | $23.01M |
| Working Capital | $43.55M | $75.09M |
Financial position
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 13.40 | 3.30 |
| Quick Ratio | 12.29 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$15.72M | -$12.39M |
Efficiency
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.20 | 0.38 |
| Revenue Per Employee | $1.00M | $398.96K |
| Profits Per Employee | -$2.71M | -$705.27K |
| Employee Count | 8 | 74 |
Dividends and yields
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -22.0% | -22.8% |
Shares
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 23,457,800 | 58,139,000 |
| Shares Change (YoY) | 22.4% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 22,250,500 | 49,154,900 |
| Shares Held by Insiders | 5.15% | 11.6% |
| Shares Held by Institutions | 33.1% | 59.4% |
Scores
| Measure | Coya Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 12.08 | -0.27 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Coya Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.